In Brief: Semglee - A New Insulin Glargine for Diabetes
Date: January 25, 2021 Issue #:  1616Summary:  The FDA has approvedSemglee (Mylan), an insulin glargine product similar toLantus, for treatment of type 1 diabetes in children and adults and type 2 diabetes in adults.Semglee is the second " follow-on " insulin glargine product to become available in the US;Basaglar, which is also similar toLantus, was the first.Lantus is a recombinant analog of human insulin that forms microprecipitates in subcutaneous tissue, prolonging its duration of action to a mean of about 24 hours with no pronounced peak effect. (Source: The Medical Letter)
Source: The Medical Letter - January 5, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Basaglar glargine insulin Lantus Semglee type 1 diabetes type 2 diabetes Source Type: research

Encorafenib (Braftovi) for Metastatic Colorectal Cancer
Date: January 25, 2021 Issue #:  1616Summary:  The FDA has approved the oral kinase inhibitor encorafenib (Braftovi– Pfizer), in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab(Erbitux), for treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. Encorafenib was approved in 2018 for use with the mitogen-activated kinase (MEK) inhibitor binimetinib(Mektovi) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. (Source: The Medical Letter)
Source: The Medical Letter - December 28, 2020 Category: Drugs & Pharmacology Authors: admin Tags: binimetinib Braftovi Cetuximab colorectal cancer encorafenib Erbitux Fluorouracil Irinotecan Leucovorin Mektovi Source Type: research

Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)
Date: December 28, 2020 Issue #:  1614Summary:  The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. Pemigatinib is the first drug to be approved i n the US for this indication. (Source: The Medical Letter)
Source: The Medical Letter - December 22, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

FDA Authorizes Moderna COVID-19 Vaccine
Date: January 25, 2021 Issue #:  1616Summary:  On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥16 years old on December 11, 2020. (Source: The Medical Letter)
Source: The Medical Letter - December 22, 2020 Category: Drugs & Pharmacology Authors: admin Tags: COVID-19 vaccines Source Type: research

Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
Date: January 11, 2021 Issue #:  1615Summary:  The FDA has approvedGimoti (Evoke), a nasal spray formulation of the dopamine-2 (D2) receptor antagonist metoclopramide, for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Metoclopramide (Reglan, and generics) has been available for years in conventional and orally-disintegrating tablets and in an injectable formulation. It is the only drug that is FDA-approved for treatment of diabetic gastroparesis. (Source: The Medical Letter)
Source: The Medical Letter - December 18, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Azithromycin diabetic gastroparesis Domperidone Erythromycin Gimoti Metoclopramide Motilium ondansetron Promethazine Reglan Scopolamine Source Type: research

Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
Date: January 11, 2021 Issue #:  1615Summary:  The FDA has approved opicapone (Ongentys– Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with Parkinson’s disease (PD) who experience " off " episodes. It is the third COMT inhibitor to be approved for this indication; tolcapone (Tasmar, and generics) and entacapone (Comtan, and generics) were approved earlier. Opicapone has been available in Europe since 2016. (Source: The Medical Letter)
Source: The Medical Letter - December 18, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Apokyn Apomorphine Carbidopa/levodopa Comtan Dopamine Entacapone Epinephrine Inbrija istradefylline Kynmobi Movapo Nourianz Ongentys opicapone Parkinson ' s disease Phenelzine Rytary selegeline Stalevo Tasmar To Source Type: research

Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Date: January 11, 2021 Issue #:  1615Summary:  The oral polymerase acidic endonuclease inhibitor baloxavir marboxil (Xofluza— Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved for treatment of acute uncomplicated influenza in patients ≥12 years old in 2018.1 Two neuraminidase inhibitors are FDA-approved for prophylaxis of influenza: oseltamivi r(Tamiflu, and generics) in patients ≥1 year old, and zanamivir(Relenza) in patients ≥5 years old.2 Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved ...
Source: The Medical Letter - December 18, 2020 Category: Drugs & Pharmacology Authors: admin Tags: baloxavir influenza Oseltamivir Relenza Tamiflu Xofluza Zanamivir Source Type: research

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
Date: January 11, 2021 Issue #:  1615Summary:  The FDA has issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA-based vaccine for prevention of COVID-19 in persons≥16 years old. (Source: The Medical Letter)
Source: The Medical Letter - December 18, 2020 Category: Drugs & Pharmacology Authors: admin Tags: COVID-19 vaccines Source Type: research

An EUA for Baricitinib (Olumiant) for COVID-19
Date: December 28, 2020 Issue #:  1614Summary:  The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant– Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be u sed in combination with the IV antiviral drug remdesivir(Veklury). Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the ...
Source: The Medical Letter - December 11, 2020 Category: Drugs & Pharmacology Authors: admin Tags: baricitinib COVID-19 Oluminat remdesivir Veklury Source Type: research

Antibacterial Drugs for Community-Acquired Pneumonia
Date: January 25, 2021 Issue #:  1616Summary:  Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019. (Source: The Medical Letter)
Source: The Medical Letter - December 4, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Amoxicillin Amoxicillin/clavulanate Ampicillin/sulbactam Antibacterials Avelox Azithromycin Baxdela Biaxin cefepime Cefotaxime Cefpodoxime ceftaroline Ceftin Ceftriaxone Cefuroxime Chlamydophila pneumoniae Clarithromycin Source Type: research

Correct Use of Inhalers for Asthma (online only)
Date: December 14, 2020 Issue #:  1613Summary:  View the table: Correct Use of Inhalers for Asthma (Source: The Medical Letter)
Source: The Medical Letter - December 4, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Some Inhaled Drugs for Treatment of Asthma (online only)
Date: December 14, 2020 Issue #:  1613Summary:  View the table: Some Inhaled Drugs for Treatment of Asthma (Source: The Medical Letter)
Source: The Medical Letter - December 4, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

An EUA for Casirivimab and Imdevimab for COVID-19
Date: December 28, 2020 Issue #:  1614Summary:  The FDA has issued an Emergency Use Authorization (EUA) for Regeneron's investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) to be administered together by IV infusion for treatment of mild to moderate COVID-19 in adults and pediatric patients ( ≥12 years old and weigh ≥40 kg) who are at high risk of progressing to severe COVID-19 and/or hospitalization (see Table 1). Bamlanivimab (LY-CoV555; Lilly), another monoclonal antibody, received an EUA for the same indication on November 9, 2020. (Source: The Medical Letter)
Source: The Medical Letter - November 24, 2020 Category: Drugs & Pharmacology Authors: admin Tags: casirivimab COVID-19 imdevimab Source Type: research

Drugs for Acne
Date: November 30, 2020 Issue #:  1612Summary:  Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment of acne were last published in 2016. (Source: The Medical Letter)
Source: The Medical Letter - November 20, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19
Date: November 30, 2020 Issue #:  1612Summary:  The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table 1). (Source: The Medical Letter)
Source: The Medical Letter - November 20, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

In Brief: New Meningococcal Serogroup B Vaccination Recommendations
Date: November 30, 2020 Issue #:  1612Summary:  The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in persons at increased risk for meningococcal disease (see Table 1). MenB booster doses were not recommended previously for any population. (Source: The Medical Letter)
Source: The Medical Letter - November 10, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Ofatumumab (Kesimpta) for Multiple Sclerosis
Date: December 28, 2020 Issue #:  1614Summary:  The FDA has approved a subcutaneous formulation of the recombinant human anti-CD20 antibody ofatumumab (Kesimpta– Novartis) for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS).Kesimpta is the second anti-CD20 antibody to be approved for these indications; IV ocrelizumab(Ocrevus), which is also approved for treatment of primary progressive MS, was the first. An IV formulation of of...
Source: The Medical Letter - November 10, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Arzerra COVID-19 Kesimpta Multiple sclerosis ocrelizumab Ocrevus Ofatumumab teriflunomide Source Type: research

IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
Date: December 28, 2020 Issue #:  1614Summary:  The FDA has approved IV amisulpride (Barhemsys– Acacia), a selective dopamine-2 and -3 (D2/D3) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes. (Source: The Medical Letter)
Source: The Medical Letter - November 10, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Aloxi amisulpride Aprepitant Barhemsys Dexamethasone Dimenhydrinate Droperidol Emend Granisetron Histanil ondansetron Palonosetron Phenergan post-operative nausea and vomiting Prochlorperazine Promethazine Scopolamine Tra Source Type: research

Remdesivir (Veklury) for COVID-19
Date: November 30, 2020 Issue #:  1612Summary:  The FDA has approved the antiviral drug remdesivir (Veklury– Gilead) for IV treatment of COVID-19 in hospitalized patients who are ≥12 years old and weigh ≥40 kg. Hospitalized children who are
Source: The Medical Letter - November 10, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
Date: November 16, 2020 Issue #:  1611Summary:  The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (Enhertu– Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib (Tukysa– Seagen), an oral tyrosine kinase inhibitor. (Source: The Medical Letter)
Source: The Medical Letter - November 6, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Minocycline Foam (Zilxi) for Rosacea
Date: November 16, 2020 Issue #:  1611Summary:  The FDA has approved a 1.5% topical foam formulation of minocycline (Zilxi– Foamix) for treatment of inflammatory lesions of rosacea in adults. It is the only topical minocycline product approved for this indication. The same manufacturer markets minocycline foam 4%(Amzeeq) for treatment of acne in patients≥9 years old. (Source: The Medical Letter)
Source: The Medical Letter - November 6, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Comparison Chart: SGLT2 Inhibitors (online only)
Date: November 16, 2020 Issue #:  1611Summary:  View the Comparison Chart: SGLT2 Inhibitors (Source: The Medical Letter)
Source: The Medical Letter - November 6, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Orphengesic Forte - An Old Analgesic Combination Returns
Date: November 16, 2020 Issue #:  1611Summary:  A fixed-dose combination of orphenadrine citrate, aspirin, and caffeine (Orphengesic Forte– Galt; previously available asNorgesic Forte) has been approved as a prescription drug by the FDA for treatment of mild to moderate pain caused by acute musculoskeletal disorders. Single-ingredient generic orphenadrine citrate is available by prescription in oral and injectable formulations and has been used for years as an adjunct for treatment of acute musculoskeletal pain.Orphengesic Forte is being marketed as a non-opioid alternative for pain relie...
Source: The Medical Letter - October 27, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Empagliflozin (Jardiance) for Heart Failure
Date: November 16, 2020 Issue #:  1611Summary:  In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance– Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart failure (HF) in patients with heart failure with reduced ejection fraction (HFrEF), whether or not they had type 2 diabetes. To date, empagliflozin has not been approved by the F DA for such use. The SGLT2 inhibitor dapagliflozin(Farxiga) was approved by the FDA for this indication earlier this year. (Sour...
Source: The Medical Letter - October 27, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

In Brief: Hydrochlorothiazide and Skin Cancer
Date: November 16, 2020 Issue #:  1611Summary:  The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide. (Source: The Medical Letter)
Source: The Medical Letter - October 27, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Expanded Table: Antiviral Drugs for Influenza (online only)
Date: November 2, 2020 Issue #:  1610Summary:  View the Expanded Table: Antiviral Drugs for Influenza (Source: The Medical Letter)
Source: The Medical Letter - October 27, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

In Brief: New Warnings on NSAID Use in Pregnancy
Date: November 2, 2020 Issue #:  1610Summary:  The FDA has required a new warning in the labels of prescription and over-the-counter products containing nonsteroidal anti-inflammatory drugs (NSAIDs) advising against their use during pregnancy beginning at 20 weeks ’ gestation because of a risk of renal dysfunction in the fetus that could lead to low amniotic fluid levels (oligohydramnios) and neonatal renal impairment. NSAID labels previously warned against use of the drugs beginning at 30 weeks'gestation because of a risk for premature closure of the ductus arteriosus and persistent neon...
Source: The Medical Letter - October 23, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Drugs for Asthma
Date: December 14, 2020 Issue #:  1613Summary:  The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations of asthma in the emergency department is not discussed here. (Source: The Medical Letter)
Source: The Medical Letter - October 13, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Large-Volume, Preservative-Free Albuterol Concentrate
Date: November 2, 2020 Issue #:  1610Summary:  The short-acting beta2-agonist albuterol sulfate has recently become available as a large-volume (20 mL), preservative-free concentrate (albuterol inhalation solution 0.5% – Nephron Pharmaceuticals) that can be used to prepare solutions for administration of continuous nebulized albuterol (CNA). CNA is commonly used (off-label) for acute treatment of severe asthma exacerbations in hospitalized patients, particularly children. Many hospitals have been using a 20-mL m ultidose bottle of 0.5% albuterol that contains the preservative benzalkonium...
Source: The Medical Letter - October 13, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

In Brief: New Benzodiazepine Warnings
Date: November 2, 2020 Issue #:  1610Summary:  The FDA now requires boxed warnings in the package inserts of benzodiazepines describing the potential for these drugs to be abused and misused and to cause addiction and physical dependence. Benzodiazepine labels have contained a boxed warning about a risk of serious drug interactions with opioids since 2016. (Source: The Medical Letter)
Source: The Medical Letter - October 13, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease
Date: November 2, 2020 Issue #:  1610Summary:  An oral extended-release formulation of the corticosteroid budesonide (Ortikos– Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending colon in patients ≥8 years old and for maintenance of remission for up to 3 months in adults.Ortikos is the second oral formulation of budesonide to be approved for this indication;Entocort EC, an ileal-release formulation, was the first. A third oral formulation of budesonide(Uceris) is approved for induction of remission in patients with...
Source: The Medical Letter - October 13, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Two New Doses of Dulaglutide (Trulicity) for Diabetes
Date: October 19, 2020 Issue #:  1609Summary:  The FDA has approved two additional doses (3 mg and 4.5 mg) of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide (Trulicity– Lilly) for treatment of type 2 diabetes in adults. Dulaglutide has been available in 0.75- and 1.5-mg doses for years. (Source: The Medical Letter)
Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy
Date: October 19, 2020 Issue #:  1609Summary:  The antisense oligonucleotide viltolarsen (Viltepso– NS Pharma) has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have mutations of the dystrophin gene that are amenable to exon 53 skipping (DMD-53). It is the second drug to be approved for this indication; the antisense oligonucleoti de golodirsen(Vyondys 53) was approved in 2019. (Source: The Medical Letter)
Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
Date: October 19, 2020 Issue #:  1609Summary:  The FDA has approved a sublingual fi lm formulation of the nonergot dopamine agonist apomorphine (Kynmobi– Sunovion) for acute, intermittent treatment of " off " episodes in patients with Parkinson's disease (PD). A subcutaneous formulation of apomorphine(Apokyn) has been available for years for the same indication in patients with advanced PD. (Source: The Medical Letter)
Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Antiviral Drugs for Influenza for 2020-2021
Date: November 2, 2020 Issue #:  1610Summary:  Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC atwww.cdc.gov/flu. (Source: The Medical Letter)
Source: The Medical Letter - September 29, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Caplacizumab (Cablivi) for iTTP
Date: October 19, 2020 Issue #:  1609Summary:  Caplacizumab-yhdp (Cablivi– Sanofi /Genzyme), a von Willebrand factor-directed antibody fragment, has been approved by the FDA for use in combination with plasma exchange and immunosuppressive therapy for treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP; formerly called acquired thrombotic thrombocyto penic purpura [aTTP]) in adults. It is the first drug to be approved in the US for this indication. (Source: The Medical Letter)
Source: The Medical Letter - September 29, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Timing of Remdesivir for COVID-19
Date: October 19, 2020 Issue #:  1609Summary:  Remdesivir (Veklury– Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use of the drug to patients hospitalized with severe disease. (Source: The Medical Letter)
Source: The Medical Letter - September 28, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Lyumjev - A New Insulin Lispro for Diabetes
Date: October 19, 2020 Issue #:  1609Summary:  The FDA has approved insulin lispro-aabc (Lyumjev– Lilly), a faster-acting formulation of insulin lispro(Humalog), for treatment of type 1 and type 2 diabetes in adults.Fiasp, a faster-acting formulation of insulin aspart(Novolog), was approved in 2017. (Source: The Medical Letter)
Source: The Medical Letter - September 14, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)
Date: September 21, 2020 Issue #:  1607Summary:  View the Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein tables (Source: The Medical Letter)
Source: The Medical Letter - September 11, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

In Brief: Canagliflozin and Lower Limb Amputations
Date: September 21, 2020 Issue #:  1607Summary:  The FDA has removed a boxed warning from the labeling of products containing the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (Invokana,Invokamet,Invokamet XR) that described an increased risk of lower limb amputation associated with use of the drug. Package inserts for canagliflozin products still contain a standard warning about a risk of lower limb amputation. (Source: The Medical Letter)
Source: The Medical Letter - September 11, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Table: Correct Use of Inhalers for COPD (online only)
Date: September 7, 2020 Issue #:  1606Summary:  View the Table: Correct Use of Inhalers for COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Advair Aerospan AirDuo Albuterol Alvesco Anoro Ellipta ArmonAir Arnuity Ellipta Asmanex Asthma Atrovent Beclomethasone Bevespi Aerosphere Breo Ellipta Breztri Aerosphere Budesonide ciclesonide Combivent COP Source Type: research

Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)
Date: September 7, 2020 Issue #:  1606Summary:  View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Advair Aermony Respiclick Alvesco ArmonAir Arnuity Ellipta Asmanex Beclomethasone dipropionate Breo Ellipta Breztri Aerosphere Budesonide Budesonide/formoterol ciclesonide COPD Flovent fluticasone furoate Fluticasone propiona Source Type: research

Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)
Date: September 7, 2020 Issue #:  1606Summary:  View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Advair AirDuo Anoro Ellipta arformoterol Bevespi Aerosphere Breo Ellipta brovana Budesonide/formoterol COPD Duaklir Genuair Duaklir Pressair fluticasone furoate Fluticasone propionate fluticasone/vilanterol Glycopy Source Type: research

Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)
Date: September 7, 2020 Issue #:  1606Summary:  View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (Source: The Medical Letter)
Source: The Medical Letter - August 31, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Albuterol Atrovent Combivent COPD Ipratropium Levalbuterol ProAir ProAir RespiClick Proventil Salbutamol Xopenex Source Type: research

A New Indication for Esketamine Nasal Spray (Spravato)
Date: September 21, 2020 Issue #:  1607Summary:  Esketamine (Spravato– Janssen), an intranasal N-methyl-D-aspartate (NMDA) receptor antagonist that was previously approved by the FDA for treatmentresistant depression,1 has now been approved for treatment of depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. E sketamine is the S-enantiomer of the anesthetic ketamine (Ketalar, and generics). It is the first drug to be approved for this indication. Most clinical trials of antidepressants have excluded patients with acute suicidal ideat...
Source: The Medical Letter - August 18, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Drugs for Migraine
Date: October 5, 2020 Issue #:  1608Summary:  An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence. (Source: The Medical Letter)
Source: The Medical Letter - August 18, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Acetaminophen acupuncture Aimovig Ajovy Almotriptan Amerge Amitriptyline Antidepressants Antiepileptics Aspirin Atenolol Aventyl Beta blockers Bisoprolol Botox Botulinum toxin Butalbital Cafergot Caffeine Cambia Can Source Type: research

Influenza Vaccine for 2020-2021
Date: September 21, 2020 Issue #:  1607Summary:  Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Available vaccines and recommendations for specific patient populations for the 2020-2021 season are listed in Ta bles 2 and 3. Lower rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures...
Source: The Medical Letter - August 18, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Drugs for COPD
Date: September 7, 2020 Issue #:  1606Summary:  The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here. (Source: The Medical Letter)
Source: The Medical Letter - August 4, 2020 Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Advair Aermony Respiclick AirDuo Airomir Albuterol Alvesco Anoro Ellipta Antibacterials arformoterol ArmonAir Arnuity Ellipta Asmanex Atrovent Azithromycin Beclomethasone dipropionate Bevespi Aerosphere Breo El Source Type: research

In Brief: An Asenapine Patch (Secuado) for Schizophrenia
Date: January 11, 2021 Issue #:  1615Summary:  A transdermal formulation of the second-generation (atypical) antipsychotic asenapine (Secuado– Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine(Saphris) has been available since 2009. (Source: The Medical Letter)
Source: The Medical Letter - July 23, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Antipsychotics Asenapine Saphris Schizophrenia Secuado Source Type: research

Ozanimod (Zeposia) for Multiple Sclerosis
Date: August 24, 2020 Issue #:  1605Summary:  The FDA has approved ozanimod (Zeposia– Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). It is the third o ral S1P receptor modulator to be approved in the US for treatment of relapsing forms of MS; siponimod(Mayzent) is also indicated for use in adults, and fingolimod(Gilenya) is approved for use in patients≥10 ye...
Source: The Medical Letter - July 21, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Arzerra Aubagio Avonex Copaxone dimethyl fumarate diroximel Fingolimod Gilenya Glatect Glatiramer acetate Glatopa Interferon beta Lemtrada Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Ofatumu Source Type: research